Cargando…
Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631518/ https://www.ncbi.nlm.nih.gov/pubmed/34858383 http://dx.doi.org/10.3389/fmicb.2021.789374 |
_version_ | 1784607579193737216 |
---|---|
author | Tian, Xiaodong Jiang, Wenguo Zhang, He Lu, XiXi Li, Libo Liu, Wenjun Li, Jing |
author_facet | Tian, Xiaodong Jiang, Wenguo Zhang, He Lu, XiXi Li, Libo Liu, Wenjun Li, Jing |
author_sort | Tian, Xiaodong |
collection | PubMed |
description | SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In this study, we used enzyme-linked immunosorbent assays (ELISA) and neutralization assay with purified SARS-CoV-2S and N proteins to study the antibody responses of 156 individuals with natural asymptomatic infection. We found robust antibody responses to SARS-CoV-2 in 156 patients from 6 to 12 months. Although the antibody responses gradually decreased, S-IgG was more stable than N-IgG. S-IgG was still detected in 79% of naturally infected individuals after 12 months of infection. Moderate to potent neutralization activities were also observed in 98.74% of patients 6 months after infection. However, this proportion decreased at 8-month (46.15%) and 10-month (39.11%) after infection, respectively. Only 23.72% of patients displayed potent neutralization activity at 12 months. This study strongly supports the long-term presence of antibodies against SARS-CoV-2 in individuals with natural asymptomatic infection, although the magnitude of the antibody responses started to cripple 6 months after infection. |
format | Online Article Text |
id | pubmed-8631518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86315182021-12-01 Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities Tian, Xiaodong Jiang, Wenguo Zhang, He Lu, XiXi Li, Libo Liu, Wenjun Li, Jing Front Microbiol Microbiology SARS-CoV-2 has caused a global health disaster with millions of death worldwide, and the substantial proportion of asymptomatic carriers poses a huge threat to public health. The long-term antibody responses and neutralization activity during natural asymptomatic SARS-CoV-2 infection are unknown. In this study, we used enzyme-linked immunosorbent assays (ELISA) and neutralization assay with purified SARS-CoV-2S and N proteins to study the antibody responses of 156 individuals with natural asymptomatic infection. We found robust antibody responses to SARS-CoV-2 in 156 patients from 6 to 12 months. Although the antibody responses gradually decreased, S-IgG was more stable than N-IgG. S-IgG was still detected in 79% of naturally infected individuals after 12 months of infection. Moderate to potent neutralization activities were also observed in 98.74% of patients 6 months after infection. However, this proportion decreased at 8-month (46.15%) and 10-month (39.11%) after infection, respectively. Only 23.72% of patients displayed potent neutralization activity at 12 months. This study strongly supports the long-term presence of antibodies against SARS-CoV-2 in individuals with natural asymptomatic infection, although the magnitude of the antibody responses started to cripple 6 months after infection. Frontiers Media S.A. 2021-11-10 /pmc/articles/PMC8631518/ /pubmed/34858383 http://dx.doi.org/10.3389/fmicb.2021.789374 Text en Copyright © 2021 Tian, Jiang, Zhang, Lu, Li, Liu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Tian, Xiaodong Jiang, Wenguo Zhang, He Lu, XiXi Li, Libo Liu, Wenjun Li, Jing Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities |
title | Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities |
title_full | Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities |
title_fullStr | Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities |
title_full_unstemmed | Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities |
title_short | Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities |
title_sort | persistence of the sars-cov-2 antibody response in asymptomatic patients in correctional facilities |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631518/ https://www.ncbi.nlm.nih.gov/pubmed/34858383 http://dx.doi.org/10.3389/fmicb.2021.789374 |
work_keys_str_mv | AT tianxiaodong persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT jiangwenguo persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT zhanghe persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT luxixi persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT lilibo persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT liuwenjun persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities AT lijing persistenceofthesarscov2antibodyresponseinasymptomaticpatientsincorrectionalfacilities |